Mb. Gariboldi et al., Resistance of human leukemic cell lines to 1-beta-D-arabinofuranosylcytosine: characterization of an experimental model, INT J ONCOL, 18(6), 2001, pp. 1245-1249
1-beta -D-arabinofuranosylcytosine (ara-C) is an antimetabolite used for th
e treatment of acute myelogenous leukemia. The ability of ara-C to kill neo
plastic cells has been correlated to the induction of apoptosis. The clinic
al use of ara-C is limited by the development of drug resistance. Alteratio
ns in drug-induced apoptosis play a critical role in ara-C resistance. In p
articular, the proto-oncogene bcl-2 has been implicated in this phenomenon.
To better understand the molecular basis of the role of bcl-2 in ara-C res
istance, we investigated the relationship between the cytotoxic effect of a
ra-C, the expression levels and the subcellular localization of bcl-2 in th
ree human leukemic cell lines (HL-60, KG1, J111). We have also evaluated th
e effects of ara-C on the J111 leukemic cell line (showing the lowest level
s of Bcl-2 and the highest sensitivity to ara-C) overexpressing the bcl-2 o
ncogene. The model we developed here will allow further studies on the role
of post-translational events involving bcl-2 (such as translocation and/or
phosphorylation) in the cellular response to ara-C treatment.